Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

BMS aims for US approval of Opdivo combo in stomach cancer

BMS aims for US approval of Opdivo combo in stomach cancer

The US Food and Drug Administration (FDA) has accepted a priority review for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) plus chemotherapy combination in stomach cancer. ... If Opdivo wins an approval for first-line gastric cancer, it could gain an

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

BMS’ Opdivo wins EU approval for second-line oesophageal cancer The survival benefit with Opdivo treatment was observed regardless of tumour PD-L1 expression levels. ... Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD) blockbuster checkpoint inhibitor Keytruda (pembrolizumab).

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

UPDATED: BMS completes $13.1bn acquisition of MyoKardia This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab).

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer In addition to Merck and Eisai, Bristol Myers Squibb (BMS) also has a new potential advanced RCC treatment in the form of a combination treatment containing its checkpoint inhibitor Opdivo (nivolumab) ... Data presented at the 2020 European Society for

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC In the phase 3 CheckMate-816 trial, Opdivo (nivolumab) was evaluated in combination with chemotherapy in patients with resectable NSCLC before surgery. ... Patients in the experimental arm of the trial received up to three doses of Opdivo plus

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics